X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SNP318 is a small molecule oral inhibitor which works by targeting Lp-PLA2, it is currently being investigated for the treatment of Alzheimer Disease.
Lead Product(s): SNP318
Therapeutic Area: Neurology Product Name: SNP318
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2023
Details:
SNP318 is a small molecule, optimized for CNS penetrance, to induce broader anti-inflammatory benefits. It is being investigated as a novel Lp-PLA2 inhibitor targeting neurodegenerative and inflammatory diseases.
Lead Product(s): SNP318
Therapeutic Area: Ophthalmology Product Name: SNP318
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2023
Details:
Under the collaboration, the companies will work together to generate novel Antisense Oligonucleotide therapies directed at targets that play a critical role in diseases of the Central Nervous System.
Lead Product(s): Antisense Oligonucleotide
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Secarna Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 27, 2023
Details:
Under the agreement, SciNeuro will receive a worldwide license to intellectual property covering certain GSK Lp-PLA2 inhibitors including SNP318 and will be responsible for their further development through clinical proof-of-concept (PoC).
Lead Product(s): SNP318
Therapeutic Area: Neurology Product Name: SNP318
Highest Development Status: IND EnablingProduct Type: Undisclosed
Recipient: GSK
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 01, 2022
Details:
SciNeuro and Mabylon will collaborate on multiple targets that encompass serious neurological diseases including TAR DNA binding protein-43 (TDP-43) and Apolipoprotein E (APOE) for neurodegenerative diseases for which there are currently no effective treatments.
Lead Product(s): Human Auto-antibodies
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Mabylon
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 26, 2021
Details:
Under the terms of the agreement, SciNeuro has obtained an exclusive license to alpha-synuclein targeted antibodies developed by Lilly, within Greater China.
Lead Product(s): Antibody therapies
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Eli Lilly
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 14, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
